Wu Y, Xue Y, Guo Z, Chen Z, Ge X, Zhong D*, Diao X* (2021). Furmonertinib (Alflutinib, AST2818) is a potential positive control drug comparable to rifampin for evaluation of CYP3A4 induction in sandwich-cultured primary human hepatocytes. Acta Pharmacol Sin.
Wu Y, Pan L, Chen Z, Zheng Y, Diao X*, Zhong D* (2021). Metabolite identification in preclinical and clinical phase of drug development. Curr Drug Metab.
Guo Z#, Liu M#, Meng J, Xue Y, Huang Q, Zheng Y, Wu Y, Chen Z, Yu J, Zhong D, Li G, Chen X, Diao X* (2021). Mechanistic study on the species differences in excretion pathway of HR011303 in human and rats. Drug Metab Dispos.
Tian Q, Zhu Y, Diao X, Zhang X, Xu Y, Jiang X, Shen J, Wang Z*, Zhong D* (2021). Species differences in the CYP3A-catalyzed metabolism of TPN729, a novel PDE5 inhibitor. Acta Pharmacol Sin.
Pan L, Yang Y, Hui M, Wang S, Li C, Zhang H, Ding Y*, Fu L*, Diao X*, Zhong D* (2021). Sulfation predominates the pharmacokinetics, metabolism, and excretion of forsythin in humans: major enzymes and transporters identified. Acta Pharmacol Sin.
Liu X, Guo Z, Chen Z, Zhang Y, Zhou J, Jiang Y, Zhao Q, Diao X*, Zhong D* (2020). Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer. Acta Pharmacol Sin.
Diao X, Huestis MA (2019). New Synthetic Cannabinoids Metabolism and Strategies to Best Identify Optimal Marker Metabolites. Front Chem.
Diao X, Huestis MA (2017). Approaches, challenges and advances in metabolism of new synthetic cannabinoids and identification of optimal urinary marker metabolites. Clin Pharmacol Ther.
Aubry AF, Christopher LJ, Wang J, Zhu M, Tirucherai G, Arnold ME. Reflecting on a decade of metabolite screening and monitoring. Bioanalysis. 2014 Mar;6(5):651-64. 2014.
Diao X, Ma Z, Wang H, Zhong D, Zhang Y, Jin J, Fan Y, Chen X (2013). Simultaneous quantitation of 3-n-butylphthalide (NBP) and its four major metabolites in human plasma by LC–MS/MS using deuterated internal standards. J Pharm Biomed Anal, 78: 19-26.
Diao X, Ma Z, Lei P, Zhong D, Zhang Y, Chen X (2013). Enantioselective determination of 3-n-butylphthalide (NBP) in human plasma by liquid chromatography on a teicoplanin-based chiral column coupled with tandem mass spectrometry. J Chromatogr B, 939: 67-72.
Diao X, Deng P, Xie C, Li X, Zhong D, Zhang Y, Chen X (2013). Metabolism and pharmacokinetics of 3-n-butylphthalide (NBP) in humans: the role of cytochrome P450s and alcohol dehydrogenase in biotransformation. Drug Metab Dispos, 41: 430-444.
W. Jian, W. Shou, N. Weng, R. W. Edom, M. Zhu. Chapter 6. LC-MS in drug metabolism and pharmacokinetics, a pharmaceutical industrial perspective. Editor, Mark Lee. Applied Spectrocopy Handbook, John Wiley & Sons, 2012.
W. Jian, M. Yao, B. Wen, E.B. Jones, M. Zhu. Chapter 15. Use of triple quadrupole-linear ion trap mass spectrometry as a single LC/MS platform in drug metabolism and pharmacokinetics studies. Editors, Mike Lee and Mingshe Zhu. Mass Spectrometry in Drug Metabolism and Disposition: Basic Principles and Applications. John Wiley & Sons, May 2011.
Obermeier MT, Yao M, Khanna A, Koplowitz B, Zhu M, Li W, Komoroski B, Kasichayanula S, Discenza L, Washburn W, Meng W, Ellsworth BA, Whaley JM, Humphreys WG. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II (SGLT2) inhibitor, in animals and humans. Drug Metab Dispos. 38(3):405-14, 2010.
M. Zhu, D. Zhang, H. Zhang, W. C. Shyu. Integrated strategies for assessment of metabolite exposure in humans during drug development: Analytical challenges and clinical development considerations. Biopharm Drug Dispos.; 30(4):163-84, 2009.
Z. Zhang, M. Zhu, and W. Tang. Metabolite profiling and identification in drug design: Current Practice and Future Directions. Curr Pharm Des. 15(19):2220-35. 2009.
M. Zhu and B. Wen. Applications of quadrupole-linear ion trap mass spectrometry to the analysis of reactive metabolites in drug discovery and development, in “Advances in Molecular Toxicology”, Volume 3, 2009. Editor, James Fishbein, Elsevier Science Ltd - Elsevier Science & Technology, July 2009.
X. Wei, and M. Zhu. Chapter 7. Regulatory considerations of drug metabolism and drug interaction studies. In “Drug Metabolism in Drug Design and Development: Basic Concepts and Practice”. Editors, Zhang, M. Zhu, W. G. Humphreys. John Wiley & Sons, October 2007.
A. Fura, Y. Shu, M. Zhu, R. Hanson, V. Roongta and W. Humphreys. Discovering drugs through biological transformation: Role of pharmacologically active metabolites in drug discovery. J. Med Chem. 47: 4339-4351, 2004.